Bmc Infectious Diseases

Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis Abstract Background: Nitric oxide (NO •) plays a pivotal role as a leishmanicidal agent in mouse macrophages. NO • resistant Escherichia coli and Mycobacterium tuberculosis have been associated with a severe outcome of these diseases.

[1]  H. Maltezou.  Nosocomial influenza: new concepts and practice , 2008, Current opinion in infectious diseases.

[2]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[3]  P. Tripathi.  Nitric oxide and immune response. , 2007, Indian journal of biochemistry & biophysics.

[4]  W. Edmunds,et al.  Precautionary Behavior in Response to Perceived Threat of Pandemic Influenza , 2007, Emerging infectious diseases.

[5]  Michiels Barbara,et al.  The effect of giving influenza vaccination to general practitioners: a controlled trial [NCT00221676] , 2006, BMC medicine.

[6]  L. Leon,et al.  Nitric oxide synthase (NOS) characterization in Leishmania amazonensis axenic amastigotes. , 2006, Archives of medical research.

[7]  L. Leon,et al.  Nitric oxide biosynthesis by Leishmania amazonensis promastigotes containing a high percentage of metacyclic forms , 2006, Archives of Microbiology.

[8]  P. Das,et al.  Isolation of a nitric oxide synthase from the protozoan parasite, Leishmania donovani. , 2006, FEMS microbiology letters.

[9]  P. Horby,et al.  Nonpharmaceutical Interventions for Pandemic Influenza, National and Community Measures , 2006, Emerging infectious diseases.

[10]  R. Pearson,et al.  Immunopathogenesis of infection with the visceralizing Leishmania species. , 2005, Microbial pathogenesis.

[11]  A. Fairlamb,et al.  Leishmania major Elongation Factor 1B Complex Has Trypanothione S-Transferase and Peroxidase Activity* , 2004, Journal of Biological Chemistry.

[12]  F. Hayden,et al.  Preventing Nosocomial Influenza by Improving the Vaccine Acceptance Rate of Clinicians , 2004, Infection Control & Hospital Epidemiology.

[13]  L. Riley,et al.  Multiclonal Leishmania braziliensis Population Structure and Its Clinical Implication in a Region of Endemicity for American Tegumentary Leishmaniasis , 2004, Infection and Immunity.

[14]  A. L. Abreu-Silva,et al.  Biological behavior of Leishmania (L.) amazonensis isolated from a human diffuse cutaneous leishmaniasis in inbred strains of mice. , 2003, Histology and histopathology.

[15]  T. Pumarola,et al.  A nosocomial outbreak of influenza during a period without influenza epidemic activity , 2003, European Respiratory Journal.

[16]  S. Sundar,et al.  NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. , 2002, Journal of medical microbiology.

[17]  Melissa A. Miller,et al.  Oxidative Responses of Human and Murine Macrophages During Phagocytosis of Leishmania chagasi1 , 2001, The Journal of Immunology.

[18]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[19]  C. Bogdan,et al.  The role of nitric oxide in innate immunity , 2000, Immunological reviews.

[20]  A. Descoteaux,et al.  Glycoconjugates in Leishmania infectivity. , 1999, Biochimica et biophysica acta.

[21]  A. Satoskar,et al.  Leishmania species: models of intracellular parasitism. , 1999, Journal of cell science.

[22]  M. Steinhoff,et al.  Effectiveness of influenza vaccine in health care professionals: a randomized trial. , 1999, JAMA.

[23]  C. Nathan,et al.  Macrophage Microbicidal Mechanisms In Vivo: Reactive Nitrogen versus Oxygen Intermediates in the Killing of Intracellular Visceral Leishmania donovani , 1999, The Journal of experimental medicine.

[24]  B. Davidson,et al.  The importance of TGF-beta in murine visceral leishmaniasis. , 1998, Journal of immunology.

[25]  M. Levick,et al.  Identification and characterisation of a functional peroxidoxin from Leishmania major. , 1998, Molecular and biochemical parasitology.

[26]  E. Cupolillo,et al.  Genetic diversity in natural populations of New World Leishmania. , 1998, Memorias do Instituto Oswaldo Cruz.

[27]  K. Dellagi,et al.  Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. , 1998, The Journal of infectious diseases.

[28]  L. Gedamu,et al.  Cloning, characterization and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: role in pathogenesis. , 1997, Molecular and biochemical parasitology.

[29]  A. Ransijn,et al.  Leishmania spp.: mechanisms of toxicity of nitrogen oxidation products. , 1997, Experimental parasitology.

[30]  F. Liew,et al.  Cytokines and nitric oxide as effector molecules against parasitic infections. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[31]  K. Kawakami,et al.  Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide. , 1997, Cellular immunology.

[32]  M. Evans,et al.  Influenza control in acute care hospitals. , 1997, American journal of infection control.

[33]  F. Fang.  Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. , 1997, The Journal of clinical investigation.

[34]  P. Debré,et al.  Interleukin‐10 and interleukin‐4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation , 1997, European journal of immunology.

[35]  B. O'Donnell,et al.  Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993–4 epidemic: results of serum testing and questionnaire , 1996, BMJ.

[36]  F. Hayden,et al.  Prevention of Nosocomial Influenza , 1996, Infection Control & Hospital Epidemiology.

[37]  C. Bogdan,et al.  Invasion, control and persistence of Leishmania parasites. , 1996, Current opinion in immunology.

[38]  N. Boéchat,et al.  Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis , 1996, The Journal of experimental medicine.

[39]  P. Debré,et al.  The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Wilson,et al.  Response of Leishmania chagasi promastigotes to oxidant stress , 1994, Infection and immunity.

[41]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[42]  N. Reiner,et al.  Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. , 1994, Immunology today.

[43]  P. Marsden,et al.  Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in Três Braços, Bahia-Brazil. , 1994, Revista da Sociedade Brasileira de Medicina Tropical.

[44]  D. Pakianathan,et al.  Trypanosoma cruzi affects nitric oxide production by murine peritoneal macrophages. , 1994, The Journal of parasitology.

[45]  E. Cupolillo,et al.  A general classification of New World Leishmania using numerical zymotaxonomy. , 1994, The American journal of tropical medicine and hygiene.

[46]  S. Moncada,et al.  Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major , 1994, European journal of immunology.

[47]  T. Evans,et al.  Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. , 1993, Journal of immunology.

[48]  H. Murray,et al.  L-arginine-dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. , 1992, The Journal of infectious diseases.

[49]  Y. Vodovotz,et al.  Macrophage deactivation by interleukin 10 , 1991, The Journal of experimental medicine.

[50]  P. Scott.  IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. , 1991, Journal of immunology.

[51]  R. Badaró,et al.  Tumor necrosis factor (cachectin) in human visceral leishmaniasis. , 1991, The Journal of infectious diseases.

[52]  R. Crawford,et al.  Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. , 1990, Journal of immunology.

[53]  E. Carvalho,et al.  Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. , 1986, The Journal of tropical medicine and hygiene.

[54]  J. Eaton,et al.  Leishmanial superoxide dismutase: a possible target for chemotherapy. , 1981, Biochemical and biophysical research communications.

[55]  R. Couch,et al.  Interpandemic influenza in the Houston area, 1974-76. , 1978, The New England journal of medicine.

[56]  A. Cruz,et al.  Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of Leishmania spp. against nitrosothiol-induced cytotoxicity. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[57]  P. Scott.  Development and regulation of cell-mediated immunity in experimental Leishmaniasis , 2003, Immunologic research.

[58]  C. Scavone,et al.  Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. , 2002, Microbes and infection.

[59]  I. Onorato,et al.  A train passenger with pulmonary tuberculosis: evidence of limited transmission during travel. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  R. Caprioli,et al.  Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. , 1995, The Biochemical journal.

[61]  J. Convit,et al.  Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. , 1993, Biological research.

[62]  D. Russell,et al.  The interaction of Leishmania species with macrophages. , 1992, Advances in parasitology.

[63]  A. Barral,et al.  Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. , 1991, Memorias do Instituto Oswaldo Cruz.

[64]  Claire Parkinson,et al.  Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. , 1990, Immunology.

[65]  D. Heyneman.  Immunology of leishmaniasis. , 1971, Bulletin of the World Health Organization.